EQRx Provides Portfolio and U.S. Commercial Strategy Updates; Reports Third Quarter 2022 Financial Results
EQRx to Hold Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022
EQRx Reports Second Quarter 2022 Financial Results and Recent Corporate Progress
EQRx reported financial results for the second quarter ended June 30, 2022 and provided an overview of recent corporate progress.
EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer
EQRx announced a late-breaking oral presentation of updated data in non-small cell lung cancer (NSCLC) at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC), taking place August 6 through August 9, 2022.
EQRx to Hold Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022
EQRx announced it will host a conference call and webcast on Thursday, August 11, 2022 at 8:00 a.m. ET to report its second quarter 2022 financial results and provide a business update.
EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer
EQRx today announced that the United Kingdom (U.K.)’s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review a marketing authorization application (MAA).